Mechanism of increased efficacy of recombinant Fc‐μTP‐L309C compared to IVIg to ameliorate mouse immune thrombocytopenia

Mechanism of increased efficacy of recombinant Fc‐μTP‐L309C compared to IVIg to ameliorate mouse immune thrombocytopenia

Abstract Recombinant Fc‐μTP‐L309C is more efficacious than intravenous immunoglobulin (IVIg) at ameliorating antibody‐mediated autoimmune diseases through its effects on Fcγ receptors (FcγRs). Fc‐μTP‐L309C inhibited in‐vitro FcγR‐mediated phagocytosis 104/105‐fold better than IVIg. Fc‐μTP‐L309C, giv...

Full description

Bibliographic Details
Main Authors: Bonnie J.B. Lewis, Beth Binnington, Megan Blacquiere, Rolf Spirig, Fabian Käsermann, Donald R. Branch
Format: Article
Language:English
Published: Wiley 2021-11-01
Series:eJHaem
Subjects:
immune thrombocytopenia
immunotherapy
ITP
ITP intravenous immunoglobulin
IVIG
IVIg
Online Access:https://doi.org/10.1002/jha2.304

Internet

https://doi.org/10.1002/jha2.304

Similar Items